Latest Insider Transactions at Zentalis Pharmaceuticals, Inc. (ZNTL)
This section provides a real-time view of insider transactions for Zentalis Pharmaceuticals, Inc. (ZNTL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Zentalis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Zentalis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2020
|
Recurium Equity, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
4,147,940
-99.64%
|
-
|
|
Apr 07
2020
|
David Michael Johnson Director |
BUY
Open market or private purchase
|
Direct |
4,000
+3.37%
|
$72,000
$18.0 P/Share
|
|
Apr 07
2020
|
Anthony Y Sun President & CEO |
BUY
Open market or private purchase
|
Direct |
888
+0.04%
|
$15,984
$18.0 P/Share
|
|
Apr 07
2020
|
Kevin D. Bunker Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
350
+0.03%
|
$6,300
$18.0 P/Share
|
|
Apr 07
2020
|
Epperly Melissa B, Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+6.3%
|
$360,000
$18.0 P/Share
|
|
Apr 07
2020
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
725,000
+14.03%
|
$13,050,000
$18.0 P/Share
|